Share Information
Other exchanges or trading platforms where Scancell Holdings plc securities are admitted or traded
Scancell Holdings securities are listed on AIM.
The number of securities in issue
The company has an issued share capital of 929,599,977 ordinary shares of 0.1p each, all of which are called up and fully paid.
Directors’ Share Options
The Company has granted the following options to current Directors of the Company.
Option holder | Option price per ordinary share | Number of ordinary shares under option | Last day of exercise period |
|---|---|---|---|
| Lindy Durrant | 10.5p | 9,000,000 | 30 January 2028 |
| Lindy Durrant | 8.15p | 1,000,000 | 30 April 2030 |
| Lindy Durrant | 4.5p | 3,850,000 | 30 July 2026 |
| Lindy Durrant | 21.25p | 9,000,000 | 9 September 2031 |
| Sath Nirmalananthan | 10.1p | 1,000,000 | 19 May 2034 |
| Jean-Michel Cosséry | 17.5p | 3,000,000 | 20 April 2033 |
| Susan Clement Davies | 17.5p | 1,000,000 | 20 April 2033 |
At 30 April 2024 there was a total of 44,564,544 outstanding share options granted by the Company, with exercise prices ranging between 4.5p and 33.2p.
Percentage of AIM securities not in public hands
As at 31 August 2024 the percentage of AIM securities not in public hands was: 42.72%
Restrictions on the transfer of securities
There are no restrictions on the transfer of shares.
Identity and percentage holdings of significant shareholders
As at 31 August 2024 the identity and percentage holdings of significant shareholders were:
Ordinary shares at 0.1p each | ||
|---|---|---|
Number | Percentage | |
| Redmile Group LLC | 268,616,936 | 28.90% |
| Vulpes Life Science Fund | 117,729,029 | 12.66% |
| Calculus Capital | 30,831,721 | 3.32% |
Director share interests
As at 31 August 2024 shares held by directors of the Company were as follows:
Ordinary shares at 0.1p each | ||
|---|---|---|
Number | ||
| Lindy Durrant | 2,069,159 | |
| Jean-Michel Cosséry | 454,545 | |
